250 completed, 165 recruiting, 123 terminated, 63 active not recruiting. 445 Phase 2, 320 Phase 1, 83 Phase 3, 27 Not applicable, 9 Phase 4.
Follow Azacitidine: new trials by email Literature Review of Azacitidine trials Research Report on Azacitidine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 122 | 2027-01-15 | 2026-10-07 |
| Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer NHT102, DryNeb - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 / Phase 2 | Not yet recruiting | Nob Hill Therapeutics, Inc. | 100 | 2027-01-11 | 2026-10-08 |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 184 | 2027-01-04 | 2026-10-01 |
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-07-09 |
| FLT3-ITD Targeted Therapy in Fit AML Patients Gilteritinib, Venetoclax, Azacitidine (AZA) - AML (Acute Myeloid Leukemia) | Phase 2 / Phase 3 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 230 | 2026-12-01 | 2026-02-23 |
| Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms Pacritinib, Venetoclax, Azacitidine - Myeloproliferative Neoplasm | Phase 1 | Not yet recruiting | Roswell Park Cancer Institute | 20 | 2026-12-01 | 2026-10-21 |
| A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy IPN60340 + azacitidine + venetoclax, Placebo + azacitidine + venetoclax - Acute Myeloid Leukaemia (AML), Acute Myeloid Leukaemia | Phase 2 / Phase 3 | Not yet recruiting | Ipsen | 540 | 2026-11-01 | 2026-09-10 |
| The Efficacy and Safety of Selinisole Combined With Azacitidine and Venetoclax in the Treatment of Newly Diagnosed High-risk Myeloid Tumors With TP53 Mutations Selinexor - Myeloid Tumors | Not applicable | Not yet recruiting | Bing Han | 30 | 2026-11-01 | 2026-06-08 |
| Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML Liposome Mitoxantrone, Venetoclax, Azacitidine - Acute Myeloid Leukemia (AML) | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2026-10-30 | 2026-09-18 |
| A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 Mutations ropeginterferon alfa- 2b, Azacitidine (AZA) - Ropeginterferon, Alfa-2b | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2026-10-27 | 2026-10-16 |
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 60 | 2026-10-27 | 2026-10-22 |
| A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients CLN-049, Azacitidine, Venetoclax - AML (Acute Myeloid Leukemia) | Phase 1 | Not yet recruiting | Cullinan Therapeutics Inc. | 90 | 2026-10-15 | 2026-07-23 |
| FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 9 | 2026-10-15 | 2026-09-17 |
| Sonrotoclax Plus Azacitidine in Patients With MDS-IB2 Sonrotoclax, Azacitidine (AZA) - Myelodysplastic Syndromes, High Risk | Phase 1 / Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 60 | 2026-10-15 | 2026-10-21 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-10-01 | 2026-08-18 |
| Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML Azacitidine, Venetoclax, Revumenib - Leukemia Acute Myeloid | Phase 2 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 88 | 2026-10-01 | 2026-09-10 |
| Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes bexmarilimab (1mg/kg), azacitidine, Placebo - Higher Risk Myelodysplastic Syndromes | Phase 2 | Recruiting | Faron Pharmaceuticals Ltd | 90 | 2026-10-01 | 2026-10-20 |
| A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia Daunorubicin, Cytarabine, Liposome Mitoxantrone - Acute Myeloid Leukemia (AML) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 320 | 2026-09-30 | 2026-08-26 |
| Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN Decitabine-cedazuridine plus venetoclax (DEC-C+VEN), Azacitidine plus venetoclax (AZA+VEN) - Relapsed / Refractory AML, High Risk Myelodysplastic Syndrome | Phase 2 | Recruiting | Virginia Commonwealth University | 40 | 2026-09-16 | 2026-09-21 |
| Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure Lisaftoclax (APG-2575), homoharringtonine, Azacitidine (AZA) - Acute Myeloid Leukemia (AML) | Phase 2 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 73 | 2026-09-01 | 2026-09-10 |
Showing 20 of 751. Sign in to see all of them.
Leukemia, Myeloid, Acute (404) · Myelodysplastic Syndromes (229) · Leukemia, Myelomonocytic, Chronic (76) · Leukemia (65) · Recurrence (36) · Myeloproliferative Disorders (25) · Neoplasms (21) · Hematologic Neoplasms (20) · Carcinoma, Non-Small-Cell Lung (18) · Multiple Myeloma (17) · Lymphoma (16) · Lymphoma, Non-Hodgkin (16) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (16) · Anemia, Refractory, with Excess of Blasts (15) · Lymphoma, T-Cell, Peripheral (15)
M.D. Anderson Cancer Center (65) · National Cancer Institute (NCI) (38) · Celgene (36) · The First Affiliated Hospital of Soochow University (29) · Institute of Hematology & Blood Diseases Hospital, China (19) · AbbVie (13) · Groupe Francophone des Myelodysplasies (12) · Novartis Pharmaceuticals (12) · Bristol-Myers Squibb (9) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (9) · Washington University School of Medicine (9) · Pfizer (8) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (8) · Beijing 302 Hospital (6) · City of Hope Medical Center (6)
United States (443) · China (165) · France (111) · Spain (86) · Germany (82) · Canada (67) · Italy (67) · Australia (66) · United Kingdom (65) · Belgium (41) · South Korea (40) · Japan (34) · Poland (32) · Czechia (30) · Taiwan (27)
Guillermo Garcia-Manero, MD (10) · Guillermo Garcia-Manero (5) · Courtney DiNardo, MD (4) · Bing Xu (3) · Brian A Jonas (3) · Courtney DiNardo (3)
PMID 24583822, PMID 25987659, PMID 26577691, PMID 27895058, PMID 29348128, PMID 30028037, PMID 31355467, PMID 33394722, PMID 34171339, PMID 35046058, PMID 35063965, PMID 35829925, PMID 36007102, PMID 36888930, PMID 37093350, PMID 37703506, PMID 37914483, PMID 38010220, PMID 38065202, PMID 38507688, PMID 38796193, PMID 39133921, PMID 39368878, PMID 39863139, PMID 40913104, PMID 42419338, PMID 16609072, PMID 17596541, PMID 18042004, PMID 19097774, PMID 19230772, PMID 19546476, PMID 19652201, PMID 19789320, PMID 20026804, PMID 20136825, PMID 20394651, PMID 20451404, PMID 20530316, PMID 20668231, PMID 21239400, PMID 21420732, PMID 21656747, PMID 22033493, PMID 22586682, PMID 22816680, PMID 22915641, PMID 23242596, PMID 23265768, PMID 23300745
2023 (14), 2016 (10), 2019 (8), P30CA006973 (8), 2015 (7), 2017 (7), 2014 (6), P30CA016672 (6), P30CA033572 (6), U01CA070095 (5), U10CA180888 (5), P30CA093373 (4), U10CA180820 (4), 2025 (3), P30CA015083 (3)